Physician profile
Anna Litvin
NPI 1629353180
$2,303.37
in general payments reported to CMS, 2019-2025
12 companies · $787 in 2025
The $787 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $550 · 2023: $497 · 2024: $330 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598 · Education: $16.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.90 |
| Education | $16.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $787.48 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $458.05 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $401.53 | 2022-2023 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $185.18 | 2024 | Iqirvo |
| Abbvie INC. | $181.31 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.48 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $65.94 | 2022 | |
| Novo Nordisk INC | $32.27 | 2021 | |
| W. L. Gore & Associates, INC. | $28.70 | 2023 | Gore Cardioform Septal Occluder |
| Alnylam Pharmaceuticals INC. | $28.09 | 2022 | |
| Intercept Pharmaceuticals, INC. | $16.63 | 2023 | Ocaliva |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Litvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.